Precision Oncology Market Advances with AI, Multi-Omics, and Tumor-Agnostic Therapies to Reach USD 317.5 Billion by 2035

Precision Oncology Market is projected to grow to USD 317.5 Billion in 2035
Precision Oncology Market projected to grow at a CAGR of 7.8% during the forecast period of 2025 to 2035

MarketGenics, a global leader in healthcare and biopharma market intelligence, announced key developments shaping the future of the rapidly expanding Precision Oncology Market.

The report highlights how AI-powered genomics, tumor-agnostic therapies, and multi-omics innovations are revolutionizing cancer treatment worldwide, enabling personalized, targeted, and highly effective cancer care.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Precision Oncology Market Research Report: https://marketgenics.co/press-releases/precision-oncology-market-55206

Recent Innovations
In April 2025, Thermo Fisher Scientific launched its Oncomine Comprehensive Multi-Omics Assay, integrating DNA, RNA, and protein profiling in a single test to improve tumor characterization and therapy selection.

In March 2025, Illumina introduced the NovaSeq X Plus platform, offering 30% faster, cost-effective next-generation sequencing (NGS) for large-scale tumor profiling.

Strategic Deals
In June 2025, a $750 million licensing agreement was signed to advance molecular glue degraders, a breakthrough class of targeted therapies for solid tumors.

Also in June 2025, AstraZeneca and Daiichi Sankyo secured FDA approval for Datroway, a biomarker-driven ADC for advanced non-small cell lung cancer (NSCLC).

To know more about the Precision Oncology Market - Download our Sample Report: https://marketgenics.co/download-report-sample/precision-oncology-market-55206

Precision Oncology Market Forecast 2035
According to the report, the global Precision Oncology Market is projected to expand from USD 139.4 Billion in 2025 to USD 317.5 Billion in 2035, growing at a CAGR of 7.8%.

The Genomics & Sequencing segment, with ~44% share in 2025, leads due to its central role in identifying actionable mutations, guiding therapy decisions, and enabling personalized treatments across diverse cancer types.

Rapid advancements in liquid biopsy tests, AI-driven analytics, and biomarker-driven targeted therapies are accelerating adoption globally.

"Precision oncology is redefining cancer care by combining deep molecular insights with advanced analytics. The rise of multi-omics and tumor-agnostic therapies is creating new treatment paradigms with unmatched precision,"

said our Senior Research Analyst at MarketGenics.

Key Driver, Restraint, and Growth Opportunity Shaping the Global Market
Driver - AI Integration in Genomics: Platforms like Tempus Edge are cutting diagnostic turnaround times by 40%, making precision oncology accessible even in community health settings.

Restraint - High Testing Costs & Limited Reimbursement: Multi-gene panels costing $3,000-$5,000 face slow adoption due to inconsistent payer coverage worldwide.

Opportunity - Tumor-Agnostic Therapies: Breakthrough approvals such as NTRK fusion-positive therapies are expanding treatment beyond tumor location, increasing eligible patient populations and driving innovation.

"The shift to tumor-agnostic treatments will broaden access to life-saving therapies and fuel the next decade of oncology innovation," added the Director of Market Strategy at MarketGenics.

Global Expansion of Precision Oncology Market
"Multi-Omics and AI Driving Personalized Cancer Care"

Multi-omics approaches are closing the gap between molecular data and therapeutic response, offering deeper insights into tumor biology.

Liquid biopsies like Guardant Health's Guardant360 CDx are reshaping non-invasive cancer diagnostics.

AI-powered platforms from companies like Caris Life Sciences are improving treatment matching and accelerating clinical decision-making.

Buy Now: https://marketgenics.co/buy/precision-oncology-market-55206

Regional Analysis of Global Precision Oncology Market
North America: Leads global adoption due to the Cancer Moonshot initiative, high R&D funding, and strong reimbursement frameworks.

Example: In August 2024, Illumina's TruSight Oncology test gained FDA clearance for multi-cancer companion diagnostics.

Europe: Expanding precision diagnostics with a focus on national genomic programs and targeted therapy access.

Asia Pacific: Rapid growth driven by investment in genomic infrastructure and expanding clinical trial networks.

Prominent Players
Key players operating in the global Precision Oncology Market include:
Illumina, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Guardant Health, Foundation Medicine, AstraZeneca, Pfizer, Novartis, Qiagen, Natera, Myriad Genetics, Invitae, Caris Life Sciences, and Other Key Players.

Recent Strategic Developments
June 2025: $750M licensing deal secured for molecular glue degraders targeting CDK2 in solid tumors, marking a shift toward highly selective protein degradation therapies.

June 2025: FDA approval of Datroway expands the biomarker-driven ADC pipeline for lung cancer, reinforcing the value of precision oncology in hard-to-treat cancers.

Get a preview of our Precision Oncology Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/precision-oncology-market-55206

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

This release was published on openPR.